Cargando…

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)

BACKGROUND: Research in treatment of non-small cell lung cancer (NSCLC) has shown promising results with stereotactic ablative radiotherapy (SABR) of oligometastatic disease, wherein distant disease may be limited to one or a few distant organs by host factors. Traditionally, PET/CT has been used in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhaliwal, Inderdeep, Kassirian, Shayan, Mitchell, Michael A., Qiabi, Mehdi, Warner, Andrew, Louie, Alexander V., Wong, Harvey H., McDonald, Christine M., Rajchgot, Jason, Palma, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047351/ https://www.ncbi.nlm.nih.gov/pubmed/35484614 http://dx.doi.org/10.1186/s12885-022-09563-8

Ejemplares similares

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
por: Palma, David A., et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
por: Olson, Robert, et al.
Publicado: (2020)

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
por: Comito, Tiziana, et al.
Publicado: (2014)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
por: Palma, David A., et al.
Publicado: (2019)

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
por: Palma, David A, et al.
Publicado: (2012)

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC
por: Badellino, Serena, et al.
Publicado: (2022)

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
por: Tjong, Michael C., et al.
Publicado: (2021)

Risk of iatrogenic pneumothorax based on location of transbronchial biopsy: a retrospective cohort study
por: Ishak, Mina, et al.
Publicado: (2023)

Technical know‐how in stereotactic ablative radiotherapy (SABR)
por: Lo, Simon S., et al.
Publicado: (2016)

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?
por: Al-Shafa, Faiez, et al.
Publicado: (2019)

Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy
por: O'Cathail, Sean M., et al.
Publicado: (2020)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists
por: Li, Shan, et al.
Publicado: (2020)

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
por: Olson, Robert, et al.
Publicado: (2018)

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
por: Goldsmith, Christy, et al.
Publicado: (2012)

SABR in oligometastatic breast cancer: Current status and future directions
por: Stewart, Rachel, et al.
Publicado: (2021)

Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)
por: Palma, David A., et al.
Publicado: (2017)

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients
por: Morales-Orue, Ignacio, et al.
Publicado: (2020)

Quantification of interplay and gradient effects for lung stereotactic ablative radiotherapy (SABR) treatments
por: Tyler, Madelaine K.
Publicado: (2016)

Stereotactic ablative radiotherapy (SABR) for recurrent and previously irradiated head and neck cancers
por: Anand, Anil Kumar, et al.
Publicado: (2020)

Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer
por: Mercier, Carole, et al.
Publicado: (2022)

Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience
por: Cuccia, Francesco, et al.
Publicado: (2023)

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
por: Franceschini, Davide, et al.
Publicado: (2021)

CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
por: Kataria, Tejinder, et al.
Publicado: (2021)

A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
por: Correa, Rohann J. M., et al.
Publicado: (2018)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
por: Hasan, Hamza, et al.
Publicado: (2020)

Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy
por: Gawish, Ahmed, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma
por: Webking, Samantha, et al.
Publicado: (2023)

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
por: Nicolae, Alexandru, et al.
Publicado: (2015)

Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia
por: Ghandourh, Wsam, et al.
Publicado: (2022)

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac
por: Janssen, Tomas M., et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy for oligometastatic inguinal lymph node in castrate resistant prostate cancer
por: Goyal, Shikha, et al.
Publicado: (2023)

Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results
por: Boda-Heggemann, Judit, et al.
Publicado: (2012)

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
por: Masucci, Giuseppe V, et al.
Publicado: (2012)

Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors
por: Binkley, Michael S., et al.
Publicado: (2016)

Restricted bowel loop contouring: Improving efficiency in radiotherapy contouring for abdomino-pelvic Stereotactic Ablative Radiotherapy (SABR)
por: Clarke, Eleanor, et al.
Publicado: (2020)

HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR)
por: Song, Chang W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s9933hdnbi627ht5kd84idllp1